Going the extra mile to keep clinical trials on track during the COVID-19 pandemic

Sofia* has breast cancer. Each month she travels from her home in Eastern Europe to a hospital in northern Italy to participate in a clinical trial. Traveling such distances for a clinical trial is uncommon, but Sofia was eager to participate in this particular trial for her condition.

But everything changed when the coronavirus (COVID-19) took hold on the continent. With transport links rapidly shutting down due to the pandemic, Sofia was no longer able to make the trip to Italy. With only two weeks’ worth of medication remaining and very little prospect of being able to obtain any …

/by

Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

  • Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease

  • Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease 
     
  • Company will also make its hydroxychloroquine intellectual property available to support broad access if …
/by

Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”

  • Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1

  • Acquisition expands the Novartis refractive disorder pipeline in ophthalmology

  • Novartis will work with Ubisoft and McGill University to accelerate product development to enable faster uptake for patients—PoC studies planned later in 2020 

Basel, April 20, 2020 — Novartis announced today that it has completed the acquisition of Amblyotech, a US-based …

/by

Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

  • Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease

     

  • Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease 
     
  • Company will also make its hydroxychloroquine intellectual property available to support broad access if …
/by

Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

  • Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease

     

  • Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease 
     
  • Company will also make its hydroxychloroquine intellectual property available to support broad access if …
/by

Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative

Novartis is teaming up with R&D leaders throughout the industry as part of the National Institutes of Health (NIH) and the Foundation for NIH (FNIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership initiative. Collaboration and open innovation are essential elements of the fight against this global pandemic. Novartis is committed to doing our part as an active contributor to the global effort underway to combat COVID-19.

About ACTIV

The National Institutes of Health and the Foundation for the NIH are bringing together more than a dozen …

/by

Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine

  • Real-world evidence supports benefits seen in Aimovig clinical trials
     
  • Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine
     
  • Post-hoc and real-world data show preventive treatment with Aimovig significantly reduces need for acute medications
     
  • These additional long-term data complement the position of Aimovig as the most prescribed anti-CGRP, with more than 350,000 patients prescribed worldwide since launch1 …
/by

Novartis ranks # 4 in PatientView’s 2019 corporate reputation survey of patient organizations

We are grateful to all patient organizations who have provided feedback on our work and take the opportunity to thank them for the hard work they are doing to support patients around the world, particularly in these challenging times of the COVID-19 crisis.

The Corporate Reputation of Pharma 2019 global report is based on the findings of a survey conducted by PatientView from November 2019 to February 2020.  

In this report Novartis ranked # 4 in overall reputation with patient organizations and # 2 in corporate brand awareness.

In our Commitment to Patients and …

/by

COVID-19: Answering your top questions

As a physician-scientist who has spent much of my career working on drug and vaccine development, including during the H1N1 pandemic, I’ve been getting many questions about my take on the COVID-19 response. I wanted to answer a few of the most common questions in case they’re on your mind as well.

How is the life sciences industry working together to combat COVID-19?

As I recently shared in an article on COVID-19, I believe we’re in the midst of by far the …

/by

Novartis completes safety review and initiates update to the Beovu® prescribing information worldwide

Basel, April 8, 2020 — Patient safety is at the heart of everything we do. Whenever adverse events are reported, we take them seriously and investigate them thoroughly.

As part of its safety surveillance program, Novartis has been actively evaluating post-marketing cases reported as severe vision loss, retinal artery occlusion and/or vasculitis with Beovu® (brolucizumab). We have been working closely with the reporting physicians and retina specialists to get their perspective and collect the relevant clinical and imaging data in a manner compliant with …

/by